*To the Editor:* Recently, the advantages of peri-operative chemotherapy in downstaging tumor and improving patient survival have been reported.^\[[@R1]\]^ Herein, we report a case of gastric cancer patient receiving neoadjuvant chemotherapy along with trastuzumab and nivolumab.

A 70-year-old Chinese man was presented to our department complaining of abdominal distension and weakness in June 2017. Complete blood count showed moderate anemia (hemoglobin, 61 g/L). A gastroscopy and biopsy led to the diagnosis of a moderately to poorly differentiated adenocarcinoma, and immunohistochemistry (IHC) indicated human epidermal growth factor receptor 2 (HER2) 2+ positivity. *HER2* gene amplification was further confirmed by fluorescence *in situ* hybridization. Computed tomography revealed a mass-like lesion (67 mm × 53 mm) located on the lesser curvature, fused with regional lymph nodes and the pancreas \[Figures [1](#F1){ref-type="fig"}A, 1D\]. Besides, several swollen lymph nodes including one para-aortic lymph node 24 mm in diameter \[Figure [1](#F1){ref-type="fig"}G\] also existed. The clinical stage was determined to be T4bN3bM0 and considered unresectable. A regimen containing chemotherapy, trastuzumab, and nivolumab was then administered: trastuzumab 8 mg/kg iv bolus followed by 6 mg/kg iv every 3 weeks, oxaliplatin 150 mg iv on day 1, S-1 60 mg bid po on day 1 to day 14, and nivolumab 200 mg iv on day 8, every 3 weeks. The clinical response was classified as a partial remission according to the Response Evaluation Criteria in Solid Tumors version 1.1 \[Figure [1](#F1){ref-type="fig"}B, 1E, and 1H\]. Due to the presence of grade 2 thrombocytopenia, in cycles 3 to 4, nivolumab and trastuzumab were maintained and the chemotherapy was administered every 2 weeks: oxaliplatin 150 mg iv on day 1, S-1 40 mg bid po on day 1 to day 10. After four cycles \[Figure [1](#F1){ref-type="fig"}C, 1F, and 1I\], a total gastrectomy (D2), Roux-en-Y esophagojejunostomy along with para-aortic lymph node resection was successfully performed in October 2017. No cancer cells were identified in the dissected lymph nodes. The residual cancer in the resected specimen was diagnosed as a moderately-differentiated adenocarcinoma. IHC showed HER2 2+ positivity. The pathological stage was ypT3N0. Post-operatively, the patient received four more cycles of the same regimens. In the 16 months of follow-up, he has remained free of disease.

![Computed tomography imaging before treatment, after two cycles, and at the end of treatment shows the mass located on the lesser curvature (A--C), mass fused with pancreas (D--F), and presence of an enlarged para-aortic lymph node (G--I).](cm9-132-1370-g001){#F1}

Furthermore, tumor mutational burden (TMB) was measured (11.1 mutations/Mb) and identified to be TMB-medium. Moreover, microsatellite instability test showed microsatellite stable phenotype. Mismatch repair (MMR) proteins were detected by IHC, which showed proficient expression of MMR proteins. IHC revealed absence of expression of programmed death-ligand 1.

Cisplatin plus S-1 is regarded as a standard first-line treatment of advanced gastric cancer (AGC) in China.^\[[@R2],[@R3]\]^ Considering the moderate anemia, physical status, and *HER2* overexpression, we chose a reduced dose of oxaliplatin, S-1, plus trastuzumab as the preferable regimen for this patient. Recently, ATTRACTION-2 study revealed the promising anti-tumor activity of nivolumab in Asian patients with advanced or recurrent gastric/gastro-esophageal junction cancer.^\[[@R4]\]^ With an unclear role of nivolumab in the peri-operative therapy, we establish the possibility of combining a checkpoint inhibitor with chemotherapy and trastuzumab in treating locally AGC. Further investigation is required to explore this combination in the peri-operative setting.
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